Itromed Gel contains Itraconazole 1% w/w, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the topical treatment of various superficial fungal infections, including dermatophytosis, candidiasis, and pityriasis versicolor. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a critical component of fungal cell membranes. Disruption of ergosterol synthesis results in increased membrane permeability and ultimately fungal cell death. Itromed Gel is applied topically to the affected area once or twice daily, depending on the severity and type of infection, and should be used for the full prescribed duration to prevent recurrence. The gel formulation allows for effective penetration into the stratum corneum, ensuring targeted antifungal activity with minimal systemic absorption. Common adverse effects are generally mild and may include local irritation, burning sensation, or erythema at the application site. Itromed Gel is contraindicated in patients with known hypersensitivity to itraconazole or any of the gel’s excipients. Caution is advised when using in pregnant or lactating women, and it should not be applied to mucous membranes or open wounds. As with all antifungals, adherence to treatment guidelines is essential to achieve optimal therapeutic outcomes and reduce the risk of resistance.